Patents by Inventor Tomoyuki Nishizaki
Tomoyuki Nishizaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10251897Abstract: The present invention provides a therapeutic drug for diabetes containing 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) as an active ingredient, particularly a therapeutic drug for diabetes that exhibits a GLUT4 endocytosis suppressive action by suppressing activation of PKC? and the like.Type: GrantFiled: January 16, 2015Date of Patent: April 9, 2019Assignee: NISHIZAKI BIOINFORMATION RESEARCH INSTITUTEInventor: Tomoyuki Nishizaki
-
Patent number: 9987208Abstract: 8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) has an action to promote synthesis and regeneration of elastin, and is useful as an agent for the prophylaxis or improvement of wrinkles, and an anti-aging drug.Type: GrantFiled: April 4, 2014Date of Patent: June 5, 2018Assignee: Nishizaki Bioinformation Research InstituteInventors: Tomoyuki Nishizaki, Akito Tanaka
-
Patent number: 9889104Abstract: The present invention provides a prophylactic and/or therapeutic drug for diabetes, which contains 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) as an active ingredient, particularly a prophylactic and/or therapeutic drug for diabetes, which promotes sugar intake into the cells, and the like.Type: GrantFiled: January 6, 2015Date of Patent: February 13, 2018Assignee: Nishizaki Bioinformation Research InstituteInventor: Tomoyuki Nishizaki
-
Patent number: 9770458Abstract: The present invention provides an anti-cancer agent, a cancer cell death inducing agent, a protein phosphatase 2A activation enhancing agent, a protein tyrosine phosphatase 1B activation enhancing agent and the like, each containing 1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine as an active ingredient.Type: GrantFiled: December 19, 2014Date of Patent: September 26, 2017Assignee: NISHIZAKI BIOINFORMATION RESEARCH INSTITUTEInventors: Tomoyuki Nishizaki, Takashi Nakano
-
Patent number: 9655911Abstract: The combined use of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine affords a superior anti-depressive action, an improving effect on the cognitive function associated with depression, an improving effect on the stress-induced suppression of Akt activation, and a suppressive action on the stress-induced GSK-3? activation. Therefore, the present invention can provide an antidepressant combination drug, an agent for improving cognitive function associated with depression, an agent for improving stress-induced suppression of Akt activation and an agent for suppressing stress-induced GSK-3? activation.Type: GrantFiled: October 14, 2014Date of Patent: May 23, 2017Assignee: Nishizaki Bioinformation Research InstituteInventor: Tomoyuki Nishizaki
-
Patent number: 9603821Abstract: 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid has a protein tyrosine phosphatase 1B (PTP1B) inhibitory action, an Akt activating action, a GSK-3? phosphorylation promoting action, and a suppressive action on ? protein phosphorylation induced by A?1-42, and is useful as a therapeutic drug for Alzheimer-type dementia, an antidepressant and/or an anti-aging drug.Type: GrantFiled: February 21, 2014Date of Patent: March 28, 2017Assignee: Nishizaki Bioinformation Research InstituteInventors: Tomoyuki Nishizaki, Akito Tanaka
-
Publication number: 20170027968Abstract: The present invention provides an anti-cancer agent, a cancer cell death inducing agent, a protein phosphatase 2A activation enhancing agent, a protein tyrosine phosphatase 1B activation enhancing agent and the like, each containing 1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine as an active ingredient.Type: ApplicationFiled: December 19, 2014Publication date: February 2, 2017Applicant: KTN BIOTEC, INC.Inventors: Tomoyuki NISHIZAKI, Takashi NAKANO
-
Patent number: 9512152Abstract: The invention provides a phospholipid compound containing unsaturated fatty acid having a cyclopropane ring such as 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) and 8-(2-octylcyclopropyl)octanoic acid (DCP-OA) and the like, particularly 1,2-o-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycero-3-phosphatidylethanolamine (diDCP-LA-PE), which has a cognitive function improving effect and an anti-diabetes action, and which is useful as a medicine such as a therapeutic drug for dementia, a therapeutic drug for diabetes and the like.Type: GrantFiled: February 14, 2014Date of Patent: December 6, 2016Assignee: Nishizaki Bioinformation Research InstituteInventors: Tomoyuki Nishizaki, Akito Tanaka
-
Publication number: 20160331769Abstract: The present invention provides a therapeutic drug for diabetes containing 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) as an active ingredient, particularly a therapeutic drug for diabetes that exhibits a GLUT4 endocytosis suppressive action by suppressing activation of PKC? and the like.Type: ApplicationFiled: January 16, 2015Publication date: November 17, 2016Applicant: NISHIZAKI BIOINFORMATION RESEARCH INSTITUTEInventor: Tomoyuki NISHIZAKI
-
Publication number: 20160324815Abstract: The present invention provides a prophylactic and/or therapeutic drug for diabetes, which contains 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) as an active ingredient, particularly a prophylactic and/or therapeutic drug for diabetes, which promotes sugar intake into the cells, and the like.Type: ApplicationFiled: January 6, 2015Publication date: November 10, 2016Applicant: NISHIZAKI BIOINFORMATION RESEARCH INSTITUTEInventor: Tomoyuki NISHIZAKI
-
Publication number: 20160235773Abstract: The combined use of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine affords a superior anti-depressive action, an improving effect on the cognitive function associated with depression, an improving effect on the stress-induced suppression of Akt activation, and a suppressive action on the stress-induced GSK-3? activation. Therefore, the present invention can provide an antidepressant combination drug, an agent for improving cognitive function associated with depression, an agent for improving stress-induced suppression of Akt activation and an agent for suppressing stress-induced GSK-3? activation.Type: ApplicationFiled: October 14, 2014Publication date: August 18, 2016Applicant: NISHIZAKI BIOINFORMATION RESEARCH INSTITUTEInventor: Tomoyuki NISHIZAKI
-
Publication number: 20160120888Abstract: An anti-cancer agent and a cancer cell death inducing agent, containing an inositol phospholipid compound, particularly 1,2-O-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycerol-3-phosphatidyl-inositol, as an active ingredient.Type: ApplicationFiled: June 6, 2014Publication date: May 5, 2016Inventors: Tomoyuki NISHIZAKI, Takashi NAKANO, Akito TANAKA, Tadashi SHIMIZU, Takeshi KANNO
-
Publication number: 20160089352Abstract: Provided is a cellular membrane trafficking promoter for a 5-HT1A serotonin receptor and the like. A cellular membrane trafficking promoter for a 5-HT1A serotonin receptor containing 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid as an active ingredient, and the like.Type: ApplicationFiled: May 15, 2014Publication date: March 31, 2016Inventors: Tomoyuki Nishizaki, Akito Tanaka
-
Patent number: 9272980Abstract: The present invention aims to provide a compound having an anticancer action comparable or superior to that of naftopidil. A compound represented by the formula (I) wherein each symbol is as defined in the SPECIFICATION, or a pharmaceutically acceptable salt thereof, particularly 1-((2-((2-methoxyphenyl)amino)ethyl)amino)-3-(1-naphthyloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof. The compound shows a cell proliferation suppressive action on a wide range of cancer cells, is useful as an anti-cancer agent, and is useful for the prophylaxis and/or treatment of cancer.Type: GrantFiled: June 6, 2014Date of Patent: March 1, 2016Assignee: KTN BioTec, Inc.Inventors: Takeshi Kanno, Akito Tanaka, Tadashi Shimizu, Takashi Nakano, Tomoyuki Nishizaki
-
Publication number: 20160045415Abstract: 8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) has an action to promote synthesis and regeneration of elastin, and is useful as an agent for the prophylaxis or improvement of wrinkles, and an anti-aging drug.Type: ApplicationFiled: April 4, 2014Publication date: February 18, 2016Inventors: Tomoyuki NISHIZAKI, Akito TANAKA
-
Publication number: 20160008308Abstract: 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid has a protein tyrosine phosphatase 1B (PTP1B) inhibitory action, an Akt activating action, a GSK-3? phosphorylation promoting action, and a suppressive action on ? protein phosphorylation induced by A?1-42, and is useful as a therapeutic drug for Alzheimer-type dementia, an antidepressant and/or an anti-aging drug.Type: ApplicationFiled: February 21, 2014Publication date: January 14, 2016Applicant: NISHIZAKI BIOINFORMATION RESEARCH INSTITUTEInventors: Tomoyuki NISHIZAKI, Akito TANAKA
-
Publication number: 20150376213Abstract: The invention provides a phospholipid compound containing unsaturated fatty acid having a cyclopropane ring such as 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) and 8-(2-octylcyclopropyl)octanoic acid (DCP-OA) and the like, particularly 1,2-o-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycero-3-phosphatidylethanolamine (diDCP-LA-PE), which has a cognitive function improving effect and an anti-diabetes action, and which is useful as a medicine such as a therapeutic drug for dementia, a therapeutic drug for diabetes and the like.Type: ApplicationFiled: February 14, 2014Publication date: December 31, 2015Inventors: Tomoyuki NISHIZAKI, Akito TANAKA
-
Publication number: 20150353473Abstract: The present invention aims to provide a compound having an anticancer action comparable or superior to that of naftopidil. A compound represented by the formula (I) wherein each symbol is as defined in the SPECIFICATION, or a pharmaceutically acceptable salt thereof, particularly 1-((2-((2-methoxyphenyl)amino)ethyl)amino)-3-(1-naphthyloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof. The compound shows a cell proliferation suppressive action on a wide range of cancer cells, is useful as an anti-cancer agent, and is useful for the prophylaxis and/or treatment of cancer.Type: ApplicationFiled: June 6, 2014Publication date: December 10, 2015Inventors: Takeshi KANNO, Akito TANAKA, Tadashi SHIMIZU, Takashi NAKANO, Tomoyuki NISHIZAKI
-
Patent number: 9012500Abstract: The present invention aims to obtain an optical isomer of DCP-LA, which shows more superior activity and is suitable for clinical utilization, and provide an agent having a superior PKC-? activation action, a prophylactic and/or therapeutic agent for neurotransmitter release disorders, and a prophylactic and/or therapeutic agent for neuropsychiatric diseases, which contain the isomer as an active ingredient. A compound represented by the following formula: or a pharmaceutically acceptable salt thereof, and a selective PKC-? activator containing same as an active ingredient, and is the like.Type: GrantFiled: November 15, 2011Date of Patent: April 21, 2015Assignee: Nishizaki Bioinformation Research InstituteInventors: Tomoyuki Nishizaki, Akito Tanaka
-
Publication number: 20130331454Abstract: The present invention aims to obtain an optical isomer of DCP-LA, which shows more superior activity and is suitable for clinical utilization, and provide an agent having a superior PKC-? activation action, a prophylactic and/or therapeutic agent for neurotransmitter release disorders, and a prophylactic and/or therapeutic agent for neuropsychiatric diseases, which contain the isomer as an active ingredient. A compound represented by the following formula: or a pharmaceutically acceptable salt thereof, and a selective PKC-? activator containing same as an active ingredient, and is the like.Type: ApplicationFiled: November 15, 2011Publication date: December 12, 2013Applicant: Nishizaki Bioinformation Research InstituteInventors: Tomoyuki Nishizaki, Akito Tanaka